RE:RE:RE:Pfizer or Roche as jv partners for the NMIBCThere won't be a buyout at this point. TLT will want to maximize our value by demonstrating what it can deliver, when compared to competition.
TLT's goal is to jv first in NMIBC to demonstrate the value of PDT/PDC and bring it to bedside. A jv will finally bring us cognition via a fairness in market valuation.
Then, with Ph. 1b in GBM and NSCLC, TLT will demonstrate that PDT/PDC can deliver in more than one field of expertises. Then, it will put itself on sale to the highest bidder, once we have Ph. 1b NSCLC and GBM efficacy data.
That's been the plan since even before treating our first NMIBC Ph. 1b. And that's exactly the maturity we're starting to aiming for.
With NMIBC FDA designation, TLT will move away from only a R&D and will enter commercialization and pharma stage levels.